Articles producció científica> Medicina i Cirurgia

Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells

  • Dades identificatives

    Identificador: imarina:3422483
    Autors:
    Corominas-Faja BCuyàs ELozano-Sánchez JCufí SVerdura SFernández-Arroyo SBorrás-Linares IMartin-Castillo BMartin ÁLupu RNonell-Canals ASanchez-Martinez MMicol VJoven JSegura-Carretero AMenendez J
    Resum:
    Targeting tumor-initiating, drug-resistant populations of cancer stem cells (CSC) with phytochemicals is a novel paradigm for cancer prevention and treatment. We herein employed a phenotypic drug discovery approach coupled to mechanism-of-action profiling and target deconvolution to identify phenolic components of extra virgin olive oil (EVOO) capable of suppressing the functional traits of CSC in breast cancer (BC). In vitro screening revealed that the secoiridoid decarboxymethyl oleuropein aglycone (DOA) could selectively target subpopulations of epithelial-like, aldehyde dehydrogenase (ALDH)-positive and mesenchymal-like, CD44+CD24-/low CSC. DOA could potently block the formation of multicellular tumorspheres generated from single-founder stem-like cells in a panel of genetically diverse BC models. Pretreatment of BC populations with noncytotoxic doses of DOA dramatically reduced subsequent tumor-forming capacity in vivo. Mice orthotopically injected with CSC-enriched BC-cell populations pretreated with DOA remained tumor-free for several months. Phenotype microarray-based screening pointed to a synergistic interaction of DOA with the mTOR inhibitor rapamycin and the DNA methyltransferase (DNMT) inhibitor 5-azacytidine. In silico computational studies indicated that DOA binds and inhibits the ATP-binding kinase domain site of mTOR and the S-adenosyl-l-methionine (SAM) cofactor-binding pocket of DNMTs. FRET-based Z-LYTE™ and AlphaScreen-based in vitro assays confirmed the ability of DOA to function as an ATP-competitive mTOR inhibitor and to block the SAM-dependent methylation activity of DNMTs. Our systematic in vitro, in vivo and in silico approaches establish the phenol-conjugated oleoside DOA as a dual mTOR/DNMT inhibitor naturally occurring in EVOO that functiona
  • Altres:

    Autor segons l'article: Corominas-Faja B; Cuyàs E; Lozano-Sánchez J; Cufí S; Verdura S; Fernández-Arroyo S; Borrás-Linares I; Martin-Castillo B; Martin Á; Lupu R; Nonell-Canals A; Sanchez-Martinez M; Micol V; Joven J; Segura-Carretero A; Menendez J
    Departament: Medicina i Cirurgia
    Autor/s de la URV: Joven Maried, Jorge
    Paraules clau: Tumorigenesis Therapy Target Protein Phenotype microarrays Junctional intercellular communication Growth Epithelial-mesenchymal transition Drug discovery Breast-cancer
    Resum: Targeting tumor-initiating, drug-resistant populations of cancer stem cells (CSC) with phytochemicals is a novel paradigm for cancer prevention and treatment. We herein employed a phenotypic drug discovery approach coupled to mechanism-of-action profiling and target deconvolution to identify phenolic components of extra virgin olive oil (EVOO) capable of suppressing the functional traits of CSC in breast cancer (BC). In vitro screening revealed that the secoiridoid decarboxymethyl oleuropein aglycone (DOA) could selectively target subpopulations of epithelial-like, aldehyde dehydrogenase (ALDH)-positive and mesenchymal-like, CD44+CD24-/low CSC. DOA could potently block the formation of multicellular tumorspheres generated from single-founder stem-like cells in a panel of genetically diverse BC models. Pretreatment of BC populations with noncytotoxic doses of DOA dramatically reduced subsequent tumor-forming capacity in vivo. Mice orthotopically injected with CSC-enriched BC-cell populations pretreated with DOA remained tumor-free for several months. Phenotype microarray-based screening pointed to a synergistic interaction of DOA with the mTOR inhibitor rapamycin and the DNA methyltransferase (DNMT) inhibitor 5-azacytidine. In silico computational studies indicated that DOA binds and inhibits the ATP-binding kinase domain site of mTOR and the S-adenosyl-l-methionine (SAM) cofactor-binding pocket of DNMTs. FRET-based Z-LYTE™ and AlphaScreen-based in vitro assays confirmed the ability of DOA to function as an ATP-competitive mTOR inhibitor and to block the SAM-dependent methylation activity of DNMTs. Our systematic in vitro, in vivo and in silico approaches establish the phenol-conjugated oleoside DOA as a dual mTOR/DNMT inhibitor naturally occurring in EVOO that functionally suppresses CSC-like states responsible for maintaining tumor-initiating cell properties within BC populations.
    Àrees temàtiques: Saúde coletiva Química Oncology Odontología Medicine (miscellaneous) Medicina iii Medicina ii Medicina i Interdisciplinar General medicine Educação física Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciência de alimentos Cancer research Biotecnología
    Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 01433334
    Adreça de correu electrònic de l'autor: jorge.joven@urv.cat
    Identificador de l'autor: 0000-0003-2749-4541
    Data d'alta del registre: 2024-09-07
    Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
    Enllaç font original: https://academic.oup.com/carcin/article/39/4/601/4857358
    URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referència a l'article segons font original: Carcinogenesis. 39 (4): 601-613
    Referència de l'ítem segons les normes APA: Corominas-Faja B; Cuyàs E; Lozano-Sánchez J; Cufí S; Verdura S; Fernández-Arroyo S; Borrás-Linares I; Martin-Castillo B; Martin Á; Lupu R; Nonell-Cana (2018). Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells. Carcinogenesis, 39(4), 601-613. DOI: 10.1093/carcin/bgy023
    DOI de l'article: 10.1093/carcin/bgy023
    Entitat: Universitat Rovira i Virgili
    Any de publicació de la revista: 2018
    Tipus de publicació: Journal Publications
  • Paraules clau:

    Cancer Research,Medicine (Miscellaneous),Oncology
    Tumorigenesis
    Therapy
    Target
    Protein
    Phenotype microarrays
    Junctional intercellular communication
    Growth
    Epithelial-mesenchymal transition
    Drug discovery
    Breast-cancer
    Saúde coletiva
    Química
    Oncology
    Odontología
    Medicine (miscellaneous)
    Medicina iii
    Medicina ii
    Medicina i
    Interdisciplinar
    General medicine
    Educação física
    Ciências biológicas iii
    Ciências biológicas ii
    Ciências biológicas i
    Ciência de alimentos
    Cancer research
    Biotecnología
  • Documents:

  • Cerca a google

    Search to google scholar